Tag: Genentech

Arcus Biosciences Announced Clinical Collaboration with Genentech

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company discovering and developing highly-differentiated therapies, announced a clinical collaboration with Genentech, a member of the Ro...

FDA Granted Priority Review for Risdiplam for SMA Treatment

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigati...

Genentech Exercised Final Option for Exclusive Target Under Agreement with Affimed

Genentech, a member of the Roche Group, has exercised its final option for an exclusive target under a collaboration agreement with Affimed N.V. to develop and commercialize novel NK cell engager-...

FDA Approved Rituxan Injection to Treat Granulomatosis with Polyangiitis

The U.S. Food and Drug Administration approved Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in ...

Enable Injections Entered into Development Agreement with Genentech

Enable Injections has entered into a development agreement with Genentech. This partnership includes the potential for multiple molecule development programs including enFuse, under development by Ena...

FDA Approved Genentech’s Rozlytrek

The U.S. Food and Drug Administration granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neuro...

Skyhawk Announced Multi-Target Exclusive Option and License Agreement with Genentech

Skyhawk Therapeutics, Inc. announced that it has entered into a multi-target exclusive option and license agreement with Genentech, a member of the Roche Group, to develop and commercialize small mole...

FDA Approves First Chemoimmunotherapy Regimen Polivy

The U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known ...

AbbVie Agreed with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®

abbvie
AbbVie, a global, research and development-driven biopharmaceutical company, announced that Ontario is the first province to reimburse VENCLEXTA® (venetoclax) monotherapy under its Drugs and Devices D...

Genentech and Parvus in Worldwide Collaboration

Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, has entered i...

Roche and Genentech’s Ocrevus Won a Recommendation from England’s NICE

Patients with Multiple Sclerosis (MS) will have routine access to a drug that can slow disability under a deal struck between NHS England and the manufacturer Roche, paving the way for its approval by...

Xencor and Genentech to Develop Novel Therapeutics

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced ...

Fifth BTD for AbbVie and Genentech Drug

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) to venetoclax, for use in c...

Genentech Announced FDA Approval for Breast Cancer Treatment

Genentech, a member of the Roche Group, announced the U.S. Food and Drug Administration (FDA) has approved Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) inj...

Priority Review for Personilized Med of Genentech

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib f...

Xencor and Genentech Entered into Agreement

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, announced it has ...